Enoxaparin Sodium EMA
approved Biosimilar

Inhixa is an Anticoagulant LMWHs (low molecular weight Heparins)

Used for Treatment and prophylaxis of DVT (Deep Vein thrombosis) with or without PE (Pulmonary Embolism) and many other approved indications.

Inhixa is used currently to treat patients across the country in both private and Governmental Hospitals

Available in following concentrations (100 ,80 ,60 ,40 ,20) mgs, as packs of 2s PFS (Prefilled Syringes)


CRYSVITA is a fibroblast growth factor 23 (FGF23) blocking antibody

indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older.

Neupogen is indicated for
the mobilisation of peripheral
blood progenitor cells (PBPCs).

Neupogen is indicated for the treatment of persistent neutropenia

(ANC less than or equal to 1.0 x 109/l) in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate. The recommended dose of Neupogen is 0.5 MU (5 mg)/kg/day. The first dose of Neupogen should be administered at least 24 hours after cytotoxic chemotherapy.

Neulastim (pegfilgrastim)

Is indicated for the reduction in the duration of neutropenia and

the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

One 6 mg dose (a single pre-filled syringe) of Neulastim is recommended for each chemotherapy cycle, given at least 24 hours after cytotoxic chemotherapy.

Neulastim is injected subcutaneously. The injections should be given into the thigh, abdomen or upper arm.